ACRV
Income statement / Annual
Last year (2025), Acrivon Therapeutics Inc's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Acrivon Therapeutics Inc's net income was -$77.91 M.
See Acrivon Therapeutics Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$1.36 M
|
$1.01 M
|
$536.00 K
|
$0.00
|
$0.00
|
$13.00 K
|
| Gross Profit |
-$1.36 M
|
-$1.01 M
|
-$536.00 K
|
$0.00
|
$0.00
|
-$13.00 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$59.99 M
|
$63.99 M
|
$45.49 M
|
$23.95 M
|
$13.72 M
|
$1.87 M
|
| General & Administrative Expenses |
$24.12 M
|
$25.21 M
|
$21.08 M
|
$8.71 M
|
$2.47 M
|
$1.30 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$134.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$24.12 M
|
$25.21 M
|
$21.21 M
|
$8.71 M
|
$2.47 M
|
$1.30 M
|
| Other Expenses |
-$1.36 M
|
-$1.01 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$82.76 M
|
$88.19 M
|
$66.70 M
|
$32.66 M
|
$16.18 M
|
$3.17 M
|
| Cost And Expenses |
$84.11 M
|
$89.20 M
|
$67.24 M
|
$32.66 M
|
$16.18 M
|
$3.17 M
|
| Interest Income |
$6.48 M
|
$9.20 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$1.36 M
|
$1.01 M
|
$536.00 K
|
$364.00 K
|
$37.00 K
|
$13.00 K
|
| EBITDA |
-$82.76 M |
-$79.55 M |
-$59.85 M |
-$32.29 M |
-$16.15 M |
-$5.29 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$6.21 M
|
$8.64 M
|
$6.85 M
|
$1.49 M
|
-$59.00 K
|
-$2.14 M
|
| Income Before Tax |
-$77.91 M
|
-$80.56 M
|
-$60.39 M
|
-$31.17 M
|
-$16.24 M
|
-$5.31 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$77.91 M
|
-$80.56 M
|
-$60.39 M
|
-$31.17 M
|
-$16.24 M
|
-$5.31 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-2.02 |
-2.1 |
-2.74 |
-1.42 |
-1.26 |
-0.41 |
| EPS Diluted |
-2.02 |
-2.1 |
-2.74 |
-1.42 |
-1.26 |
-0.41 |
| Weighted Average Shares Out |
$38.51 M
|
$38.30 M
|
$22.08 M
|
$21.92 M
|
$12.91 M
|
$12.91 M
|
| Weighted Average Shares Out Diluted |
$38.51 M
|
$38.30 M
|
$22.08 M
|
$21.92 M
|
$12.91 M
|
$12.91 M
|
| Link |
|
|
|
|
|
|
